Spherium Biomed announces positive outcome of a phase I/IIa clinical trial for Mucomel®

Share on linkedin
Share on twitter
Share on email

Spherium Biomed announced on May 17, 2018 that it has obtained positive results with its new drug Mucomel® in a phase I/IIa clinical trial for the prevention and treatment of oral mucositis in patients of head and neck cancer treated with chemo and radiotherapy.

It has been shown that Mucomel® reduces the incidence of severe mucositis to almost half of patients. In addition, in patients who develop mucositis, its duration is shortened with a reduction considered clinically very relevant by physicians who have participated in the study.

Spherium reported that it is negotiating with international partners the co-development of the clinical phase III of the drug, which is expected to be available in the market by approximately 2022.

ABG IP is proud to have collaborated with Spherium Biomed in the IP protection of Mucomel® and other products in the companies’ pipeline.

ABG IP
ABG is a leading European IP firm. ABG’s more than 60 professionals combine experience, outstanding technical knowledge and deep legal expertise to be at the forefront of IP law.
ABG IP on EmailABG IP on Linkedin

Share this post with interested parties

Share on linkedin
Share on twitter

Subscribe to our newsletter

Next Events

No event found!

Relevant news

patents korea japan

Patents in Japan and South Korea

Both Japan and South Korea are countries with a long track record in Industrial Property. Not surprisingly, they have significant scientific and technological potential that

Read More »